News

Richmond-based manufacturer expands operations to reduce waste, pollution and cost in the laboratory industry

Seven years after its founding as a startup business in Richmond, Grenova Inc. has moved into a new phase of development as a company.

“We have been growing quite significantly,” said Ali Safavi, the founder and CEO of Grenova, which has a mission to reduce waste, pollution and costs in the global laboratory industry. Grenova, which stands for Green Innovation, announced plans in April to relocate its operations from a 10,000-square-foot facility in the Manchester area of South Richmond to a 35,000-square-foot building at 1900 Ellen Road just north of Scott’s Addition. The company also announced plans to invest $10.6 million to expand its production and hire 250 people over the next three years. The newly renovated facility – formerly occupied by Sampson Coatings Inc. – is now operating as Grenova’s main office, research and development and manufacturing facility, with more than 60 employees.

Grenova designs and manufactures equipment that health care businesses, universities and government agencies can install in their laboratories to wash and sterilize plastic pipette tips, the small tools used to transfer samples in medical diagnostic tests and research projects such as drug development. Grenova’s goal from the start has been to reduce the billions of pounds of plastic pipette tips that are discarded after one use and end up in landfills.

“About every two and half years, we have tripled our footprint,” said Safavi, noting that the company started in 2014 in a 3,200 square foot office in Midlothian before moving to Manchester and now to the site on Ellen Road. At the new facility, the company can make up to 2,800 cleaning and sterilization units per year, per work shift, Safavi said. That’s up from a capacity of just a few hundred units at its previous location.

To learn more please visit Richmond Times-Dispatch

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and